A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors

Investigational New Drugs · Published 2026-07-07 · DOI 10.1007/s10637-026-01626-y

Authors (14)

Daruka Mahadevan, Jay Parekh, Joseph T. Beck, Willam B. McKean, Karisa C. Schreck, Anthony J. Olszanski, Misty D. Shields, Vu Phan, John T. Hamm, Bruce B. Bank, Jianli Zhou, Marc Chamberlain, Kishor Bhatia, Reginald Ewesuedo

Abstract

PubPorta does not have an abstract for this article yet.

Read the article at the publisher →

Publication details

Year

2026

Citation

Mahadevan, D., Parekh, J., Beck, J., et al. (2026). A first-in-human phase 1a study of LP-184, a tumor-site activated novel alkylating agent, in patients with advanced solid tumors. Investigational New Drugs. https://doi.org/10.1007/s10637-026-01626-y

Related articles

• Association of different approvals with Chinese Society of Clinical Oncology recommendation levels for solid tumor drugs: a cross-sectional analysis · Investigational New Drugs · 2025 · Same journal
• Clinical potential of antibody–drug conjugates in early-phase clinical trials for late-line treatment of advanced solid tumors · Investigational New Drugs · 2025 · Same journal
• Anti-CD47 tri-specific killer engager enhances NK cell cytotoxicity against lung cancer · Investigational New Drugs · 2025 · Same journal
• A phase I study of TRK-950, an Anti-CAPRIN-1 antibody, as monotherapy and in combination with nivolumab in Japanese patients with advanced solid tumors · Investigational New Drugs · 2026 · Same journal
• Beyond the obvious: targeting the SLC transportome and non-canonical drug transport mechanisms in cancer therapy · Investigational New Drugs · 2025 · Same journal
• Crocetin suppresses colorectal cancer progression by targeting TGM2 and inhibiting the JAK2/STAT3 pathway · Investigational New Drugs · 2026 · Same journal
• ABCB1 and ABCC10 polymorphisms predict sensitivity to first- and third-generation EGFR-TKIs in EGFR-mutant NSCLC · Investigational New Drugs · 2025 · Same journal
• Class-level DILI saturation and hERG-driven risk stratification among 2024–2025 FDA-approved kinase inhibitors: an in silico multi-platform safety analysis · Investigational New Drugs · 2026 · Same journal
• Selective cytotoxicity of solamargine via oxidative stress and caspase-independent mechanisms in human glioblastoma cells · Investigational New Drugs · 2026 · Same journal
• Patient-derived tumor organoids for new drug development: promises and challenges · Investigational New Drugs · 2026 · Same journal